EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Capecitabine in combination with oxaliplatin as first line therapy for patients with advanced or metastatic colorectal cancer Preliminary results of an international multicenter phase II study



Capecitabine in combination with oxaliplatin as first line therapy for patients with advanced or metastatic colorectal cancer Preliminary results of an international multicenter phase II study



European Journal of Cancer 37(Supplement 6): S272, October




(PDF emailed within 1 workday: $29.90)

Accession: 034527597

Download citation: RISBibTeXText



Related references

Cetuximab + capecitabine + irinotecan (CCI) versus cetuximab + capecitabine + oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): Preliminary results of a randomized phase II trial of the AIO CRC Study Group. Journal of Clinical Oncology 24(18_suppl): 3550-3550, 2016

A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Cancer ChemoTherapy and Pharmacology 73(4): 799-806, 2014

A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (pts) with advanced or metastatic colorectal cancer (MCRC). Journal of Clinical Oncology 24(18_suppl): 13540-13540, 2016

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Annals of Oncology 24(6): 1580-1587, 2013

Preliminary results of a randomized phase III trial of the TTD Group comparing capecitabine and oxaliplatin (CapeOx) vs. oxaliplatin and 5-fluorouracil in continuous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer (CRC). Journal of Clinical Oncology 23(16_suppl): 3524-3524, 2016

Phase II multicenter sequential study of oxaliplatin (O) and capecitabine (C) followed by irinotecan (I) and capecitabine (C) in first line advanced colorectal cancer (CRC). Journal of Clinical Oncology 23(16_suppl): 3544-3544, 2016

Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. Annals of Oncology 19(6): 1154-1159, 2008

Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Bmc Cancer 14(): 277-277, 2014

Capecitabine plus oxaliplatin (XELOX) followed by capecitabine plus irinotecan (XELIRI) in a sequential schedule in first-line metastatic colorectal cancer (MCRC): a phase II multicenter study. Journal of Clinical Oncology 24(18_suppl): 13516-13516, 2016

Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study. Oncology 74(1-2): 31-36, 2008

Phase II randomized trial on protracted 5-fluorouracil infusion plus oxaliplatin (FOX) versus capecitabine plus oxaliplatin (XELOX) as first-line treatment in advanced colorectal cancer (ACRC): Preliminary results of the Italian FOCA Study. Journal of Clinical Oncology 23(16_suppl): 3617-3617, 2016

Capecitabine plus irinotecan vs capecitabine plus oxaliplatin as first-line therapy of advanced colorectal cancer Updated results of a randomized phase II Trial. EJC Supplements 1(5): S90-S91, September, 2003

Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer. Anti-Cancer Drugs 19(8): 825-831, 2008

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. Bmc Cancer 14(): 883-883, 2015

CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer Preliminary results of a phase I/II study. European Journal of Cancer 37(Supplement 6): S296, October, 2001